A Multicenter Open-Label, Long-Term Extension Study of WA22762 and NA25220 to Evaluate Safety and Efficacy of Subcutaneous Tocilizumab in Patients With Moderate to Severe Rheumatoid Arthritis
Phase of Trial: Phase III
Latest Information Update: 18 Oct 2016
At a glance
- Drugs Tocilizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Registrational
- Sponsors Genentech
- 31 Aug 2018 Biomarkers information updated
- 07 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 29 Oct 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.